ImmuCell (NASDAQ:ICCC – Get Free Report) and Vaxart (OTCMKTS:VXRT – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership and earnings.
Risk & Volatility
ImmuCell has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Vaxart has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations and price targets for ImmuCell and Vaxart, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ImmuCell | 0 | 1 | 0 | 0 | 2.00 |
| Vaxart | 0 | 1 | 0 | 0 | 2.00 |
Insider and Institutional Ownership
13.5% of ImmuCell shares are held by institutional investors. Comparatively, 18.0% of Vaxart shares are held by institutional investors. 5.7% of ImmuCell shares are held by company insiders. Comparatively, 2.8% of Vaxart shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares ImmuCell and Vaxart”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ImmuCell | $27.64 million | 3.74 | -$1.04 million | $0.08 | 142.31 |
| Vaxart | $237.26 million | 0.37 | $16.33 million | $0.13 | 2.80 |
Vaxart has higher revenue and earnings than ImmuCell. Vaxart is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares ImmuCell and Vaxart’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ImmuCell | 5.66% | 6.25% | 4.15% |
| Vaxart | 16.02% | 35.14% | 17.10% |
Summary
Vaxart beats ImmuCell on 8 of the 11 factors compared between the two stocks.
About ImmuCell
ImmuCell is an animal health company focused on products for cattle. It develops, manufactures and markets products intended to support the health of dairy and beef herds. Its best-known product line, First Defense, consists of oral antibody products given to newborn calves to help protect against common causes of scours, a form of calf diarrhea. The products are designed to provide targeted antibodies during the early stages of life. ImmuCell has also developed Re-Tain, a non-antibiotic product for subclinical mastitis in dairy cows.
About Vaxart
Vaxart, Inc. is a clinical-stage biotechnology company developing oral vaccines for infectious diseases. Its proprietary platform is designed to deliver vaccine candidates in tablet form and to stimulate immune responses at mucosal surfaces as well as throughout the body. The company’s investigational programs have included vaccines for norovirus, seasonal influenza and COVID-19. These candidates remain in development and are not approved vaccines. Based in South San Francisco, California, Vaxart focuses on research and development and may work with external partners to advance its vaccine programs.
Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.
